Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Research Grants 60 show all


$2.9M
2014

$6.2M
2015

$3.2M
2016

$16.5M
2017

$7.1M
2018

Publications 107 show all

  • 10
    Factor Xa Inhibitors
  • 10
    Platelet Membrane Glycoproteins/metabolism
  • 7
    Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
  • 6
    Blood Platelets/physiology
  • 5
    Blood Platelets/metabolism
  • 5
    Peptides/pharmacology
  • 5
    Platelet Aggregation Inhibitors/chemical synthesis
  • 5
    Platelet Aggregation Inhibitors/pharmacology
  • 5
    Platelet Glycoprotein GPIIb-IIIa Complex/metabolism
  • 4
    Thrombin/metabolism

Patents 32,998show all

  • 6,090
    C07D - Heterocyclic compounds
  • 5,823
    A61K - Preparations for medical, dental, or toilet purposes
  • 3,029
    C07K - Peptides
  • 1,283
    C07C - Acyclic or carbocyclic compounds
  • 1,248
    C12N - Microorganisms or enzymes
  • 1,103
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 778
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 569
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 566
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 458
    C07H - Sugars

Clinical Trials 2,086show all

540Phase 3392N/A371Phase 2349Phase 1146Phase 4101Phase 1/Phase 230Other

Contact Information

Chuo
Japan